Ronit Bendori

Ronit joined Evergreen in mid 2000 as a General Partner. She focuses on Evergreen's investments in the Healthcare sector. Prior to joining Evergreen, Ronit was the Vice President of Pharmos Ltd. (NASDAQ: PARS). Before Pharmos Ronit held senior positions as an expert in technology transfer at InterPharm Ltd. (Israel) and Ares-Serono (Switzerland). As one of its most experienced figures, Ronit is an active promoter of Israeli Healthcare industry. She was an adviser to former Chief Scientists at the Israeli Ministry of Industry and Trade on biotechnology issues. On behalf of the chief scientist she headed the Monitor Survey of the Israeli Biotechnology. Currently, she is a member of the advisory board of the Israeli Scientific American and on the advisory board of the Center for Women's Health at Hadassah Hospital, Jerusalem. Ronit has taught Industrial Aspects of Biotechnology in various institutions, including the Weizmann Institute of Science. She has a Ph.D in molecular and cellular biology from the Weizmann Institute of Science. Ronit initiated and was responsible for Evergreen's investment in Colbar, which was sold to Johnson & Johnson for $160M. Ronit was Colbar's Chairperson and worked with the company from its early days till its acquisition. Ronit represents Evergreen on the boards of following medical device companies: Activiews,Corassist, Nephera, Niti, Notal and Peer Medical.